Global Gastrointestinal Partnering 2015-2022: Deal trends, players and financials

Wildwood Ventures
350+ Pages - WILD10961
$3,495.00

Global Gastrointestinal Partnering 2015 to 2022 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015.

Trends in Gastrointestinal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Gastrointestinal partnering agreement structure
Gastrointestinal partnering contract documents
Top Gastrointestinal deals by value
Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2015. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2015 to 2022 includes:

Trends in Gastrointestinal dealmaking in the biopharma industry since 2015
Access to headline, upfront, milestone and royalty data
Access to hundreds of Gastrointestinal deal contract documents
Comprehensive access to over 500 Gastrointestinal deal records
The leading Gastrointestinal deals by value since 2015
Most active Gastrointestinal dealmakers since 2015

The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2015 to 2022, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 500 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

'

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Gastrointestinal dealmaking

2.1. Introduction
2.2. Gastrointestinal partnering over the years
2.3. Gastrointestinal partnering by deal type
2.4. Gastrointestinal partnering by industry sector
2.5. Gastrointestinal partnering by stage of development
2.6. Gastrointestinal partnering by technology type
2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 –Financial deal terms for Gastrointestinal partnering

3.1. Introduction
3.2. Disclosed financials terms for Gastrointestinal partnering
3.3. Gastrointestinal partnering headline values
3.4. Gastrointestinal deal upfront payments
3.5. Gastrointestinal deal milestone payments
3.6. Gastrointestinal royalty rates

Chapter 4 – Leading Gastrointestinal deals and dealmakers

4.1. Introduction
4.2. Most active in Gastrointestinal partnering
4.3. List of most active dealmakers in Gastrointestinal
4.4. Top Gastrointestinal deals by value

Chapter 5 – Gastrointestinal contract document directory

5.1. Introduction
5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 – Gastrointestinal dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Gastrointestinal therapeutic target

Appendices

Appendix 1 – Directory of Gastrointestinal deals by company A-Z 2015 to 2022
Appendix 2 – Directory of Gastrointestinal deals by deal type 2015 to 2022
Appendix 3 – Directory of Gastrointestinal deals by stage of development 2015 to 2022
Appendix 4 – Directory of Gastrointestinal deals by technology type 2015 to 2022
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Gastrointestinal partnering since 2015
Figure 2: Gastrointestinal partnering by deal type since 2015
Figure 3: Gastrointestinal partnering by industry sector since 2015
Figure 4: Gastrointestinal partnering by stage of development since 2015
Figure 5: Gastrointestinal partnering by technology type since 2015
Figure 6: Gastrointestinal partnering by indication since 2015
Figure 7: Gastrointestinal deals with a headline value
Figure 8: Gastrointestinal deals with upfront payment values
Figure 9: Gastrointestinal deals with milestone payment
Figure 10: Gastrointestinal deals with royalty rates
Figure 11: Active Gastrointestinal dealmaking activity– 2015 to 2022
Figure 12: Top Gastrointestinal deals by value since 2015

4D Pharma, 4SC, 9 Meters Biopharma, AB Analitica, Abbvie, Ab E Discovery, Adacyte Therapeutics, AdaptVac, ADL Bionatur Solutions, Advanced Medical German Company of Kuwait, Aerpio Pharmaceuticals, Aevi Genomic Medicine, Aexis Medical, AIDS Clinical Trials Group, AIG Hospitals, Akebia Therapeutics, Akeso Biopharma, Akkadeas Pharma, Alab, Alba Therapeutics, Albireo, Alfasigma, Alimentary Health, Alivio Therapeutics, Allergan, Alma Bio Therapeutics, Almirall, Alnylam Pharmaceuticals, Altos Group, Alvine Pharmaceuticals, Alvit LCS Pharma, Alvotech, Amarex Clinical Research, Ambry Genetics, Ambu, Americas Hernia Society Quality Collaborative, Amgen, Amneal Pharmaceuticals, Amunix, Anatara Lifesciences, Angelini Pharma, AnimalBiome, ANI Pharmaceuticals, Anokion, Antibe Therapeutics, Apharm, Apotex, Applied BioMath, Applied Molecular Transport, Arcadia Consumer Healthcare, Arc Medical Design, Ardelyx, Arena Pharmaceuticals, Ariel Precision Medicine, Aries Pharmaceuticals, Aristea Therapeutics, Artizan Biosciences, Asana Medical, Ascension Health Ventures, AscentX Medical, Asklepion Pharmaceuticals, Aslan Pharma, Assembly Biosciences, Astellas Pharma, AstraZeneca, Asymchem Laboratories, Atlantic Healthcare, Auggi, Aurobindo Pharma, Australasian Gastro Intestinal Research Foundation, Azelis, Aziyo Biologics, AzurRx BioPharma, Back-A-Line, Bausch Health Companies, Baxalta, Baxter International, Bayer Healthcare, Bazelet, B Braun, BC Children's Hospital, BDD Pharma, Beacon Discovery, Becton Dickinson, Beijing Podconley Pharmaceutical Technology and Development, Best Choice, BHR Pharma, Bill and Melinda Gates Foundation, BIO-CAT Microbials, Bio-Me, Bio-Rad Laboratories, Bio-Thera Solutions, BioClinica, Biocodex Microbiota Foundation, BioDelivery Sciences, Biofortis, Biogen, BIOgenetiX, Biohaven Pharmaceutical, Biohit, BiomeBank, Biomecite Diagnostics, Biomedical Advanced Research and Development Authority, Biomedica Medizinprodukte, BioMed X Innovation Center, Biomerica, BiomX, Bioportugal Quimica Farmaceutica, BioRap Technologies, Biostage, BioStorage Technologies, BioSurfaces, Boditech Med, Boehringer Ingelheim, Boston Pharmaceuticals, Bpifrance, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Buchang Pharmaceutical, Calypso Biotech, Camargo Pharmaceutical Services, Cambridge Clinical Laboratories, CannaKids, Cannex Scientific, Cantel Medical, CapsoVision, Capsulomics, Captor Therapeutics, Cara Care, Carbiotix, Case Western Reserve University, Casper Pharma, Catalent, CB2 Therapeutics, CDx Diagnostics, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Celimmune, Celltrion, Celsius Therapeutics, Censis Technologies, Cerevance, Cernostics, Certara, Charles River Laboratories, Cheplapharm Arzneimittel, Children's Hospital of Philadelphia, Chinese University of Hong Kong, CHU Sainte-Justine, Cipher Pharmaceuticals, Cipla, CIRCA Scientific, CJ Corp, Cleveland Clinic, Clinigen, CN Bio, Codexis, Coherus Biosciences, Commonwealth Laboratories, Complix, Concordia Pharmaceuticals, Connecticut Children’s Medical Center, ConvaTec, Cook Biotech, Cook Medical, Cornell University, Cosmo Pharmaceuticals, COUR Pharmaceutical, C R Bard, Creapharm, CRH Medical, Crohn's and Colitis Foundation of America, CRS Bio, Curant Health, CURE Pharmaceutical, Cyclerion Therapeutics, Cytocom, CytoReason, Daewoong Pharmaceutical, Daiichi Sankyo, Dalriada Drug Discovery, Danish Innovation Fund, Debiopharm, Deciphex, Delphi Genetics, Department of Defense, Dermira, Diagnoplex, Diagnostic International Distribution, Diversigen, Dong-A ST, Dr. Falk Pharma, Dr. Reddy's Laboratories, Duke Clinical Research Institute (DCRI), EA Pharma, Eclipse Regenesis, ECM Therapeutics, Edenbridge Pharmaceuticals, Eisai, Elanco, Eli Lilly, Endo-Therapeutics, Endo International, EndoLogic, enGene, Engitix, Entellus Medical, Entera Health, Enterome Bioscience, Entrinsic Health Solutions, Epirus Biopharmaceuticals, Erbe Elektromedizin, EsoCap, EtectRx, Ethicon Endo-Surgery, Eunice Kennedy Shriver Institute of Child Health and Human Development, European Union, Eversana, EvoEndo, Evoke Pharma, Evolve BioSystems, Evommune, Evotec, Ewopharma, Exact Sciences, Exalenz Bioscience, ExeGi Pharma, Faes Farma, Felix Biotechnology, Ferring Pharmaceuticals, Fiagon, Finch Therapeutics, First Wave Bio, Food and Drug Administration (FDA), Food Marble Digestive Health, Fosun Pharmaceutical, Foundation for Celiac Disease Outcome Measures, Frazier Healthcare Ventures, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, FSD Pharma, Fujifilm, Fujifilm Kyowa Kirin Biologics, Functional Gut Diagnostics, Galapagos, Galena Biopharma, Gemelli Biotech, Genentech, General Automation Lab Technologies, Genetic Analysis, Genten Therapeutics, Georgia State University, Gilead Sciences, Ginkgo BioWorks, GI OnDEMAND, GI Partners of Illinois, GI Reviewers, GI Supply, GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, Great Belief International, Grunenthal, Grupo Ferrer, Gurnet Point Capital, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Haisco Pharmaceutical, Harvard Apparatus Regenerative Technology, Harvest Capital Strategies, Hawaii Medical, Healthcare Royalty Partners, Helsinn Healthcare, Henry Schein, HiFiBio, Highland Therapeutics, Hollister-Stier Labs, Holobiome, Horizon 2020, Hoth Therapeutics, Hudson Institute of Medical Research, Humabs BioMed, Icahn School of Medicine at Mount Sinai, Idera Pharmaceuticals, Illumina, IMIDomics, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Immunic, ImmunogenX, Immunostics, Impax Laboratories, Imperial College London, Inception Sciences, Indegene Lifesystems, InDex Pharmaceuticals, Indiana Biosciences Research Institute, Infirst HEALTHCARE, Innocoll, INNOVAMEDICA, Innovate Biopharmaceuticals, Innovation Pharmaceuticals, Innovet, InQpharm, Insightra Medical, Institut Gustave Roussy, Instituto de Ciencias Farmaceuticas, Intas Pharmaceuticals, International Centre for Diarrhoeal Disease Research, Interscope, Intract Pharma, Intralytix, Intrexon, IntroMedic, InveniAI, Ionis Pharmaceuticals, Ipsen, IQVIA, Ironwood Pharmaceuticals, ISA Scientific, ISOThrive, Iterative Scopes, Jaguar Health, Jamieson, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Jitsubo, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Juventas Therapeutics, Kansas University Medical Center (KUMC), Kanyos, Karl Storz, Karolinska Institute, Karo Pharma, Keio Gijuku University, Kennedy Trust For Rheumatology Research, Kenneth Rainin Foundation (KRF), Kerry, KineMed, Kings College London, Knight Therapeutics, Koligo Therapeutics, Korea Pharma, Kwang Dong Pharmaceutical, Kyowa Hakko Kirin, Laboratories Acbel, Laboratorios Bago, Laborie Medical Technologies, Lamassu Pharma, Landos Biopharma, Leading BioSciences, Lead Pharma, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, LianBio, Lipid Therapeutics, LiveLeaf, LMU University Hospital Munich, LNC, Lonza, Lucid Diagnostics, Luminex, Lycera, Magellan Health Services, Magnet Sales and Manufacturing, Mannheim Pharma & Diagnostics, Marinomed Biotechnologie, Massachusetts General Hospital, Massachusetts Institute of Technology, Mauna Kea Technologies, Maxer, Mayo Clinic, McMaster University, McNeil Consumer Pharmaceuticals, Medgenics, MediBeacon, Medical Innovations Group, Medical Measurement Systems, Medical University of Graz, Medical University of Vienna, Medigus, MedImmune, Medline Industries, Meiji Seika, Memorial Hermann Health System, Meridian Bioscience, Meritage Pharma, Merit Medical Systems, Mesoblast, Metabiomics, Metagenics, Micro-Tech Endoscopy, Microba Life Sciences, Microbiotica, Microline Surgical, Midatech, Millennium, Mimetas, Mission Cure, MiTest Health, Mitsubishi Tanabe Pharma, Mobidiag, Molteni Farmaceutici, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, MorphoSys, Mor Research Applications, Motus GI Medical Technologies, Motus Therapeutics, MSN Pharmaceuticals, MultiPlan, Mundipharma, MyBiotics Pharma, Mylan Laboratories, Mylan Pharmaceuticals, Naia Pharma, Nanjing Micro-Tech, Napo EU, Napo Pharmaceuticals, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Nektar Therapeutics, Neoteryx, Nestle Health Science, Neurogastrx, NeuTec Pharma, Nexus Medical, Ninepoint Medical, Norgine, Northeastern University, Northwestern University, North Zealand University Hospital, NovaMedica, Novartis, Novartis Institute for Tropical Diseases, Noventure, Novigenix, Novome Biotechnologies, Novo Nordisk, NPS Pharmaceuticals, NuBiyota, Numab, NuMedii, Numerate, Nutriband, Nutricion, NYU Langone Medical Center, Olympus, Olympus Medical Systems, Omega Pharma, Onegevity, Orgenesis, Origin Biosciences, OSE Immunotherapeutics, Otsuka America Pharmaceutical, Owlstone Medical, Palisade Bio, Palobiofarma, Panaxia, PanTheryx, Paragon Bioservices, ParaPRO, Parexel, Parexel Biotech, Parvus Therapeutics, Path BioAnalytics, Patheon, PAVmed, PEAR Therapeutics, Pendopharm, Penn State Microbiome Center, Pentax, Perelman School of Medicine, PerkinElmer, Perrigo, Pfizer, PharmaCare Management, PharmaSwiss, Phathom Pharmaceuticals, Pierre Fabre, PlantEXT, Pliant Therapeutics, Polpharma, Portal Instruments, PPD, Prana Biotechnology, PredictImmune, Premier Inc, Prescient Medical, PRISM BioLab, Probi, ProciseDx, Progenity, Progressive Medical International, Progressive Spinal Technologies, Prometheus Biosciences, Prometheus Laboratories, Pronutria, Protagonist Therapeutics, Provention Bio, Proxy Biomedical, Purdue Pharma, PureTech Health, PvP Biologics, Qualicaps, Qu Biologics, Queen Mary University of London, Quest Diagnostics, Quest Products, Quotient Clinical, Rafa Pharmaceuticals, RDD Pharma, ReadSense Genomic Center, Rebiotix, Reckitt Benckiser, Recordati, RedHill Biopharma, Regentys, Renexxion, Repligen, ReproCell, ResearchMatch, Retrophin, Rising Pharmaceuticals, Ritter Pharmaceuticals, Roche, Romark Laboratories, Royalty Pharma, Salix Pharmaceuticals, Samsung Bioepis, Sandoz, Sanofi, Saphena Medical, Satisfai Health, SciCann Therapeutics, Scipher Medicine, Scripps Research Institute, Second Genome, Seed Health, Seed Mena, Selexis, Sentia Medical Sciences, Sequana Medical, Seres Therapeutics, Shandong Luoxin Pharma, Shionogi, Shire Laboratories, Shire Pharmaceuticals, Signet Healthcare Partneers, Signum Surgical, Simulations Plus, Sinovant Sciences, Sloan Pharma, Smart Medical Systems, Soligenix, SomaLogic, SonarMD, Sosei, Sosei Heptares, Spectramed, SpectraScience, SPI Pharma, Starton Therapeutics, Stella Diagnostics, Steris Corporation, Strand Life Sciences, Stratis Medical, Structural Genomics Consortium, Summit Pharmaceuticals / Alliance Labs, Sun Genomics, Suono Bio, Sutter Health, Swedish Orphan Biovitrum, Swiss Integrative Center for Human Health, Swixx Biopharma, Symbiotix Biotherapies, Synergy Pharmaceuticals, Synlab, Synlogic, Synthetic Biologics, Taewoong Medical, Takeda Pharmaceutical, Tantu Therapeutics, TARGET PharmaSolutions, Telcon RF Pharmaceuticals, Teligent, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Texas A&M Health Science Center, The Crohn's and Colitis Foundation of Canada, The HUB Foundation, Theradiag, Theranostica, Theravance, Theravance Biopharma, The Vancouver Island Health Authority, Thorne Research, Tianyin Pharmaceutical, TiGenix, Tillotts Pharma, Tissium, Tiziana Life Sciences, Torax Medical, TransEnterix, Twist Bioscience, TxCell, UCB, Unilabs, Unilever, UniQuest, United Digestive, Universite catholique de Louvain, University College Cork, University of Adelaide, University of Augsburg, University of Birmingham, University of British Columbia, University of Calgary, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Manitoba, University of Maryland Ventures, University of Massachusetts, University of North Carolina, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sherbrooke, University of Tokyo, University of Washington, University of Windsor, Upadia, Utrecht University, Valbiotis, Valeant Pharmaceuticals, Vcell Healthcare, V ClinBio, Vedanta Biosciences, Vedco, Verily, Vertex Pharmaceuticals, Via Surgical, Vinnova, VIPUN Medical, Virginia Catalyst, Virios Therapeutics, Vital Food Processors, Vital Therapies, Vivante Health, Vivelix Pharmaceuticals, Vizient, Washington University in St Louis, Weill Cornell Medical College, WELL Health, Wockhardt, WuXi Biologics, Xoma, Yale University, Yissum Research Development, Zealand Pharma

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838